Lexeo Therapeutics (LXEO) investor relations material

Pipeline focus and clinical progress

• Lead programs target Friedreich's ataxia (FA) and arrhythmogenic cardiomyopathy (PKP2 mutation), with FA in a registrational study and PKP2 in phase I with a readout expected by year-end.

• FA program shows 2.5–3-point mFARS improvement and 28% LVMI reduction at six months, exceeding the 15% threshold needed for the pivotal study.

• PKP2 program targets a 60,000-patient rare disease, with high-dose data showing up to 65% reduction in non-sustained ventricular tachycardia at nine months.

• Both programs use AAVrh10-mediated vectors, with PKP2 showing dose-dependent increases in protein expression and favorable safety to date.

• Key catalysts include PKP2 data and regulatory updates in 2026, FA top-line readout in 2027, and BLA filing in early 2028.

Study design, endpoints, and regulatory strategy

• FA pivotal study uses randomized allocation to untreated control and treatment arms, with LVMI as the primary endpoint and mFARS, troponin, and KCCQ as secondary endpoints.

• Natural history data suggest negligible LVMI change in controls, supporting the study's design and powering.

• FDA has deprioritized frataxin expression as an endpoint, focusing on LVMI due to its clinical relevance and link to mortality.

• Confirmatory evidence strategy for mFARS is pending with the FDA, with potential for longer-term follow-up in the same study.

• All untreated control patients can cross over to treatment at six months, and their data will be included in the analysis.

Commercial and operational outlook

• CMC strategy benefits from FDA CDRP pilot, allowing fit-for-purpose PPQ requirements and streamlined process validation.

• Commercial build-out targets heart failure specialists, a concentrated group of 4,000–5,000 physicians, enabling efficient market access.

• Cash position of $234 million provides runway into 2028, supporting pivotal trial completion and BLA filing.

• Capital allocation prioritizes the LX2006 pivotal program, with burn rate expected to rise as trials progress.

• Access and reimbursement strategy for FA cardiomyopathy may hinge on troponin as a biomarker for therapy initiation.